Skip to main content

miR-198 inhibits the progression of renal cell carcinoma by targeting BIRC5



miR-198 is involved in the formation, migration, invasion, and metastasis of various malignant cancers. However, the function and mechanism of action of miR-198 in the tumorigenesis of renal cell carcinoma (RCC) remain elusive. Here, we aimed to explore the role of miR198 in RCC.


Immunohistochemistry was performed to estimate the level of survivin in RCC sections. Quantitative real-time polymerase chain reaction was performed to determine the expression level of miR-198 in fresh RCC tissues. Furthermore, the target relationship between miR-198 and BIRC5 was predicted using the TargetScanHuman 7.2 database and verified via dual-luciferase reporter assay and western blotting. The effects of miR-198 on the viability, apoptosis, invasion, and migration of A498 and ACHN cells were studied using Cell Counting Kit-8, flow cytometry, transwell migration assay, and wound healing assay, respectively. Additionally, a xenograft nude mouse model was established to evaluate the effect of miR-198 on RCC tumorigenesis.


The expression levels of BIRC5 and miR-198 were respectively higher and lower in RCC tissues than those in normal adjacent tissues. Furthermore, miR-198 could inhibit luciferase activity and reduce the protein level of survivin without affecting the BIRC5 mRNA levels. miR-198 inhibited cell viability, migration, and invasion and promoted cell apoptosis; co-transfection with BIRC5 could rescue these effects. Moreover, miR-198 could repress tumor growth in the xenograft nude mouse model of RCC.


Our study demonstrates that miR-198 suppresses RCC progression by targeting BIRC5.


Renal cell carcinoma (RCC) is the most invasive and common renal cancer in adults. Globally, the number of RCC cases is increasing annually owing to the presence of multiple etiologies, [1]. Furthermore, only up to 10% of patients with RCC present with characteristic clinical symptoms due to the lack of early warning signs [1]. Approximately 30% of patients with RCC present with metastases at the time of diagnosis [2]. RCC is resistant to radiotherapy and chemotherapy, and early diagnosis and successful surgical resection can save the patient’s life [1]. The 5-year survival rate of patients with stage I, II, III, and IV renal cancer after treatment is 92, 86, 64, and 23%, respectively [3]. These data suggest that the early diagnosis and prediction of renal cancer leads to an increased patient survival rate. In recent years, advanced drugs for malignant RCC that interfere with molecular targets involved in tumor growth and development have been used in clinical practice[2,3,4]. The developed drugs, including everolimus, sunitinib, and axitinib have achieved remarkable results but have not cured patients [4,5,6]. Therefore, it is crucial to identify biomarkers of RCC and explore their molecular mechanisms to design new therapy targets for RCC.

MicroRNAs (miRNAs) are small non-coding RNAs that are responsible for the post-transcriptional regulation of gene expression by targeting their corresponding mRNA. The abnormal expression of miRNA has been correlated to various diseases, including cancers [7]. Dysregulated miRNAs are considered novel tumor inhibitors or oncogenes vital for the development and progression of cancer [8]. miR-198 has reportedly played an essential role in many cancers, including lung, breast, gastric, and liver cancers [9,10,11,12]. To illustrate, Hu et al. revealed that miR-198 acted as a tumor suppressor in aggressive breast cancer by not only inhibiting cell proliferation and migration but also promoting cell adhesion [11]. However, Liang et al. reported that miR-198 induced oncogenesis of lung cancer via upregulating livin expression [13]. However, the role of miR-198 in renal tumors has not been currently elucidated.

BIRC5 gene, the whole neme is Baculoviral inhibitor of apoptosis repeat-containing 5, which encodes the Survivin protein, i.e., the smallest member of the inhibitor of apoptosis family. BIRC5 is involved in many cancers, and the survivin protein has been identified as a cancer biomarker [14,15,16]. BIRC5 regulates cancer development by inhibiting cell apoptosis and inducing cell proliferation [17]. Additionally, increasing evidence demonstrates that BIRC5 is influences the aggressiveness of clear-cell RCC, and a high survivin expression level predicts a poor patient outcomes [18].

In this study, we aimed to explore the role of miR-198 in renal carcinoma and reveal its underlying molecular mechanism.


Clinical specimens

Thirty sets of kidney specimens, including renal carcinoma tissues and adjacent normal tissues, were collected from patients who underwent surgical resection of tumors at Haikou Municipal Hospital affiliated to Xiangya School of Medicine of Central South University from June 2016 to June 2018. This study was approved by the Ethics Committee of Hubei Polytechnic University and Haikou Municipal Hospital. All patients provided written informed consent.


RCC tissues and adjacent tissues were stained with an antibody against survivin (10,508–1-AP, Proteintech), secondary antibody (GB23303; Servicebio), and diaminobenzidine reagent (DAB Horseradish Peroxidase Color Development Kit; Beyotime) following a previously described method [19]. The stained tissues were imaged using an Olympus microscope at × 200 and × 400.

Cell culture

The human RCC cell line A498 and ACHN (China Center for Type Culture Collection, Wuhan, China) were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Hyclone) containing 10% fetal bovine serum (FBS; Hyclone) in a cell incubator (Thermo) with 5% CO2 at 37 °C. Cell transfection was performed with Lipofectamine™ 2000 reagent (Invitrogen) according to the manufacturer’s instructions.


The 600-bp 3′-UTR (untranslated region) of BIRC5, which encodes survivin, was amplified by polymerase chain reaction (PCR) using human genomic DNA as the template. The PCR product was digested with SacI and HindIII and cloned into the pMIR-REPORT™ luciferase vector (Promega), resulting in a plasmid encoding a luciferase reporter protein BIRC5-WT. The miR-198 binding site in the 3′-UTR of the gene encoding BIRC5-WT was mutated using point mutation by PCR as previously described [20] so that the mutant gene encodes reporter BIRC5-MUT. The BIRC5 eukaryotic expression plasmid FLAG-BIRC5 was cloned from cDNA and inserted into pCDNA3.1-FLAG (Addgen) with KpnI and HindIII restriction sites. The primers used are listed in Table 1. miR-198 mimic, miR-198 inhibitor, and scrambled miRNA mimic were synthesized by RioboBiO (Guang Zhou, China).

Table 1 The primers for plasmids

Extraction of total RNA and quantitative real-time PCR

Total RNA was extracted from the clinical samples and cell lines using TRIzol reagent (TaKaRa). Complementary DNA (CDNA) of BIRC5 was reverse transcribed from RNA using HiScript II Q RT SuperMix (R223-01, Vazyme). mRNA expression was determined by quantitative reverse transcription PCR (QRT-PCR) with ChamQ™ SYBR® qPCR Master Mix (Q311-02, Vazyme) using QuantStudio Q5 (Applied Biosystems). GAPDH was used as the internal reference for BIRC5 mRNA. The relative expression of the genes was calculated using the 2−ΔΔCt method. The following primers were used for quantitative PCR:









miR-198 quantification was performed using the following protocol: CDNA of miR-198 and U6 were reverse transcribed using miRNA 1st Strand cDNA Synthesis Kit (MR101-01, Vazyme) with miR-198 RT primer (ssD809230220, RioboBiO) and U6 RT primer (ssD0904071008, RioboBiO), respectively. Then we estimated the miR-198 expression level in the miR-198 CDNA library using miRNA Universal SYBR qPCR Master Mix (MQ101-01) with miR-198 forward (ssD809230912, RioboBiO) and reverse (ssD089261711, RioboBiO) primers. Furthermore, we tested the U6 expression level in the U6 cDNA library with U6 forward (ssD0904071006, RioboBiO) and reverse (ssD0904071007, RioboBiO) primers.. The data were normalized to the U6 expression level and analyzed using the 2−ΔΔ Ct method (Additional file 2).

Western blots

A498 and ACHN cells were transfected with the indicated miR-198 or scrambled miRNA mimic for 48 h. Total protein was then extracted from the cells using radioimmunoprecipitation assay (RIPA) lysis buffer (Beyotime) according to the manufacturer’s protocol. Next, the cell lysates were subjected to western blotting with antibodies against survivin (10508-1-AP, Proteintech), β-tubulin (HRP-66031, Proteintech) or β-Actin (GB11001, Servicebio) (Additional file 2).

Each group of tumor tissues in the mouse model was assessed for survivin expression; 20 mg of tumor tissues were weighed and quick-frozen in liquid nitrogen, followed by homogenization with 500 μl RIPA lysis buffer. After homogenization, the lysates were incubated in a 4 °C shaking table for 2 h to allow further lysis; the lysates were then centrifuged at 13000 g × 10 min, 4 °C. The supernatant was mixed with loading buffer and boiled at 100 °C for 15 min, then stored at − 80 °C.

Dual-luciferase reported assay

Luciferase assays were performed as described previously [20]. Briefly, A498 and ACHN cells cells were cultured in a 24-well plate and co-transfected with 150 ng of BIRC5-WT or BIRC5-MUT plasmid with 100 nM miR-198, scrambled mimic of miR-198, or 10 ng of pRL-TK vector (Promega). After 48 h, the cells were lysed, and the lysates were used for luciferase assays using the Dual-Glo Luciferase Assay kit (Promega). Fluorescence was measured using the Promega GloMaxTM 20/20 Luminometer, and luciferase activity was normalized with the ratio of fluorescence values of firefly luciferase and Renilla luciferase.

Cell viability assay

A498 and ACHN cells were seeded in a 96-well plate and transfected with a scrambled mimic of miR-198, miR-198, and miR-198 + FLAG-BIRC5 for 0, 24, and 48 h. Then, cell viability was determined using a Cell Counting Kit-8 Kit (Dojindo Laboratories, Japan) according to the manufacturer’s instructions. Cell viability was determined by measuring the absorbance at 450 nm using a microplate reader. We regarded the absorbance at 450 nm as the cell viability rate.

Cell cycle assay

The effect of miR-198 on the cell cycle in RCC was assayed using the Cell Cycle Staining Kit (Beyotime). After transfection with miR-198 or its scrambled mimic for 48 h, A498 cells were washed with phosphate-buffered saline (PBS), trypsinized, fixed in 70% ice-cold ethanol, and incubated with 100 mg/mL RNase and 4 mg/mL propidium iodide (PI) in PBS. The cell cycle phase of the cells was analyzed using a flow cytometer (FC500; Beckman Coulter) and was analyzed using CXP software (Beckman Coulter).

Apoptosis assay

The effects of miR-198 on cell apoptosis were measured using the Annexin V-FITC/PI apoptosis detection kit (Beyotime) according to the manufacturer’s instructions. A498 and ACHN cells cells were transfected with a scrambled mimic of miR-198, miR-198, and miR-198 + FLAG-BIRC5 for 48 h and then treated with puromycin aminonucleoside (100 µg/mL) for 48 h to induce apoptosis. The cells were then washed twice with cold PBS, digested with trypsin with EDTA, neutralized with DMEM, and harvested. After washing with cold PBS two times, the cells were then resuspended in 200 µL of binding buffer and stained with 5 µL of Annexin V-FITC and 10 µL of PI at room temperature for 15 min. Cell apoptosis was analyzed using a Coulter FC500 instrument. The flow cytometry data were analyzed using CXP software. We calculated the percentage of apoptotic cells by the percentage of cells in the upper right quadrant (Annexin V-FITC-positive, PI-positive) and cells in the lower right quadrant (Annexin V-FITC positive, PI-negative).

Wound healing assay

A498 and ACHN cells were transfected with a scrambled mimic of miR-198, miR-198, and miR-198 + FLAG-BIRC5. After 36 h, the cells in the middle of the well were scratched using a 10 μL pipette tip. The cells were visualized under × 100 magnification (Olympus microscope) at 0 and 24 h after scratching, and the extent of cell migration was analyzed using ImageJ software.

Transwell assay

A498 and ACHN cells were transfected with a scrambled mimic of miR-198, miR-198, and miR-198 + FLAG-BIRC5 for 48 h. Next, the cells were digested, resuspended, and plated in a transwell chamber (Corning) previously coated with Matrigel 1:8 diluted with serum-free DMEM (BD), with 100 µL of serum-free DMEM, while out the part with 500 µL of 10% FBS DMEM. The cells in the transwell chamber were cultured for 12 h in an incubator, fixed with methyl alcohol for 20 min, stained with 0.1% crystal violet for 10 min, washed several times with 1 × PBS, and imaged at 40 × using an Olympus light microscope. The number of invasive cells was counted using ImageJ software.

Xenograft tumor model

The mouse studies were approved by the Ethics Committee of Hubei Polytechnic University. Male BALB/C-nu/nu nude mice aged 6–8 weeks were used in the experiments. A498 cells were transfected with miR-198, its specific inhibitor, or its scrambled mimic for 48 h. The cells were then harvested, washed with cold PBS, and suspended at a density of 5 × 106 cells/mL in PBS. The well-treated A498 cells, at a density of 5 × 105 cells/100 μL, were injected subcutaneously in the lateral side of the right rear leg (n = 6). Tumor diameters were measured using vernier calipers every 2 days, and tumor volumes were calculated using the formula (width2 × length/2). The mice were sacrificed at the end of each experiment, and tumors were excised, weighed, imaged, and fixed for further characterization.

Statistical analysis

Orange 8.5 and GraphPad Prism 6.0 software were used for statistical analyses. All data were presented as means ± standard deviations. A t-test and one-way ANOVA (analysis of variance) were used to compare differences between groups. P < 0.05 was considered statistically significant.


Expression of BIRC5 in RCC

We investigated the role of BIRC5 in RCC by characterizing its expression using quantitative PCR and immunohistochemistry (IHC). BIRC5 was overexpressed in 7 RCC patients compared with that in adjacent tissues (Fig. 1C). The level of survivin was assayed using IHC with the survivin antibody, and RCC tissues exhibited intense survivin staining (Fig. 1A–B). Surprisingly, Zhang et al. also reported a high expression of BIRC5 in RCC tissues and RCC cell lines, especially in A498 cells [21]. These results suggest that BIRC5 contributes to RCC.

Fig. 1
figure 1

BIRC5 is overexpressed in renal cell carcinoma. A Fifteen pairs of renal cell carcinoma (RCC) tissues and adjacent tissues were subjected to immunohistochemistry staining to characterize the level of survivin. B Statistical analysis. Analysis of the positive signal (IOD) of survivin in RCC and adjacent tissues using image pro plus 6.0. ****P < 0.0001. C qRT-PCR was performed to compare the mRNA expression of BIRC5 in RCC and adjacent tissues. The expression of BIRC5 was significantly upregulated in RCC tissues

miR-198 suppresses BIRC5 expression

To get predicted targets of miR-198, Huang et al. conducted the prediction process online via 14 miRNA database and selected 127 mRNAs as the predicted targets [22]. BIRC5 was of particular interest since its expression has been identified as a cancer biomarker in many types of cancers [14,15,16]. Using TargetScan Human 7.2 database, we located one binding sites for miR-198 at the 3 ‘UTR of the BIRC5 mRNA, however the miR-198 site within BIRC5 3'UTR is not conserved (Fig. 2A). To verify weather the miR-198 binds to BIRC5 3'UTR, we cloned the wild-type and mutated 3′-UTR of BIRC5 into a pMIR-reporter vector as BIRC5-WT and BIRC5-MUT, respectively, and performed dual-luciferase reporter assay in A498 and ACHN cells. The luciferase activity of the cells co-transfected with miR-198 and BIRC5-WT was significantly lower than that of the cells co-transfected with the scrambled mimic and BIRC5-WT; in contrast, the co-transfection of miR-198 and BIRC5-MUT did not affect the luciferase activity (Fig. 2C–D). These results indicate that miR-198 could bind to the 3′-UTR of BIRC5 in RCC. We also examined the expression of miR-198 in eight pairs of fresh RCC tissues and adjacent tissues using quantitative PCR. The expression of miR-198 in RCC tissues was significantly lower than that in adjacent tissues (Fig. 2B). Furthermore we porfermed the QRT-PCR and Western blot to assessed the effect of miR-198 on BIRC5 expression, and found that miR-198 did not affect the mRNA expression of BIRC5 (Fig. 2E) but decreased the level of survivin (Fig. 2F–G). These results show that miR-198 is bound to the 3′-UTR of BIRC5 and suppressed the level of survivin.

Fig. 2
figure 2

miR-198 decreases the expression of BIRC5. A Bioinformatics analysis of miR-198 and BIRC5 using TargetScanHuman 7.2. The graphic model of the binding site of miR-198 in the 3′-UTR of BIRC5. B qRT-PCR. miR-198 expression was quantified in 7 pairs of fresh RCC and adjacent tissues. C Luciferase assay. A498 and ACHN cells were co-transfected with BIRC5-WT + pRL-TK, mimic + BIRC5-WT + pRL-TK, miR-198 + BIRC5-WT + pRL-TK, and miR-198 + BIRC5-MUT + pRL-TK; The cells were harvested 48 h later for dual-luciferase assay. D Point mutation model of BIRC5 dual-luciferase reporter vector. BIRC5-WT is the luciferase reporter vector with wild-type BIRC5 3′-UTR, and BIRC5-MUT is the luciferase reporter vector with BIRC5 3′-UTR with a mutated miR-198 binding site. E A498 cells were treated with the scrambled mimic and miR-198; After 48 h, qRT-PCR was performed. **P < 0.01; ****P < 0.0001. F A498 cells were treated as described in (E); after 48 h, the cell lysates were subjected to western blotting with survivin and tubulin antibodies. ****P < 0.0001. G ACHN cells were treated with the scrambled mimic and miR-198; after 48 h, the cells underwent western blotting analysis with indicated antibodies. ****P < 0.0001

miR-198 promotes the apoptosis of RCC cells and inhbits the cell viability

BIRC5 reportedly plays a crucial role in RCC development, including in cell viability, metastasis, and survival [21]. Our previous results confirmed that miR-198 can decrease the protein expression level of BIRC5 (Fig. 2). Thus, we studied the effects of miR-198 on RCC development by transfecting the A498 and ACHN cells with scrambled mimic, miR-198, and miR-198 + FLAG-BIRC5 and measuring cell viability, apoptosis, and cell cycle experiments. We examined the viability of A498 and ACHN cells in 96-well plates at 0, 24, and 48 h three times and found that miR-198 suppressed the viability of RCC cells and BIRC5 blocked the effect of miR198 (Fig. 3D–E). Additionally, apoptosis assays showed that miR-198 increased the apoptosis of RCC cells, whereas co-transfection with BIRC5 could rescue the apoptosis (Fig. 3A–C). Furthermore, we performed the cell cycle assay and found that miR-198 did not affect the cell cycle (Additional file 1: Fig. S1). These results reveal that miR-198 might impede cancer cell development through apoptosis by suppressing BIRC5 expression.

Fig. 3
figure 3

miR-198 affects cell growth. A Apoptosis assay. A498 and ACHN cells were transfected with the scrambled mimic, miR-198, and miR-198 + FLAG-BIRC5 for 36 h, following which, they were treated with 100 μg/ml of puromycin for 36 h, and analyzed using flow cytometry. B Statistical analysis of the apoptosis rate in A498 cells in (A). **P < 0.01. C Statistical analysis of the apoptosis rate in ACHN cells in (A). ****P < 0.0001. D CCK8 assay of A498 cells. A498 cells were transfected with the scrambled mimic, wild-type miR-198 and miR-198 + FLAG-BIRC5. Then, 5 μL of CCK-8 solution was added to the cells, and cell viability rate was determined using an enzyme marker at 0, 24, and 48 h. *, P < 0.05; **P < 0.01. E CCK8 assay of ACHN cells. ACHN cells were treated as described in (D). *P < 0.05

miR-198 decreases the migration and invasion capabilities of RCC

Understanding how tumor cells develop heterogeneity, invade local tissues, and spread to distant tissues is a primary goal of cancer research [23]. Therefore, we studied the role of miR-198 in RCC progression using wound healing assay and transwell assay. A498 and ACHN cells were transfected with scrambled mimics of miR-198, miR-198, and miR-198 + FLAG-BIRC5. After 36 h, the cells were subjected to the wound healing and transwell assays. The wound healing assay results showed that, compared with the control group, miR-198 overexpression inhibited the migration of RCC cells in miR-198 group, and BIRC5 co-expression with miR-198 reversed this effect (Fig. 4A–C). Similarly, the transwell assay results showed that miR-198 overexpression significantly decreased the invasion ability of RCC cells and that BIRC5 suppressed this effect of miR-198 (Fig. 4D–F). These results suggest that miR-198 suppressed cancer cell development by inhibiting cancer cell migration and invasion.

Fig. 4
figure 4

miR-198 regulates cell migration and invasion. A A498 and ACHN cells were transfected with the scrambled mimic of miR-198, wild-type miR-198, and miR-198 + FLAG-BIRC5; after 36 h, cells were analyzed using the wound healing assay, and the results were determined at 0 and 24 h. B Statistical analysis of the cell migration ratio of A498 cells using Image J. ****P < 0.0001. C Statistical analysis of the cell migration ration of ACHN cells. ****P < 0.0001. D Transwell assay. A498 and ACHN cells were treated as described in (A), after 36 h, the cells were digested, resuspended, and cultured in a Matrigel-coated transwell chamber and tested for invasion after 12 h. E Statistical analysis of cell invasion of A498 cells using Image J. ****P < 0.0001. F Statistical analysis of cell invasion of ACHN cells. ****P < 0.0001

miR-198 inhibits RCC growth in vivo

The results of the in vitro experiments suggested that miR-198 inhibited RCC via inhibiting cell viability, migration and invasion and promoting apoptosis (Figs. 3 and 4). Then, we evaluated whether miR-198 affected renal tumor growth in vivo using a xenograft tumor model. We transfected A498 cells with miR-198, miR-198 scrambled mimic, or miR-198 inhibitor. We injected the transfected cells into nude mice, monitored tumor growth by measuring tumor length and width every 2 days, and excised the tumor after 22 days. Compared with the scrambled mimic, miR-198 could suppress the renal tumor size, whereas the miR-198 inhibitor could block the repressive effect of miR-198 on renal tumor size (Fig. 5A). The growth curve of a renal tumor showed that miR-198 could slow the tumor growth rate, and its effect was blocked by miR-198 inhibitor (Fig. 5C). In addition, we observed a similar result on the effect of miR-198 and its variants on tumor weight (Fig. 5B). Furthermore, we investigated the expression of survivin in each group of tumor tissues through western blotting and found that, compared with the mimic group, the expression of survivin was downregulated in the miR-198 group, and the miR-198 inhibitor could block its downregulation (Fig. 5D). Data from the in vivo tumor model suggest that miR-198 suppresses renal tumor growth.

Fig. 5
figure 5

miR-198 inhibits the growth of renal cell carcinoma. A498 cells were transfected with the scrambled mimic of miR-198, wild-type miR-198, or miR-198 inhibitor. After 36 h, the cells were collected and injected into nude mice (n = 6). Each tumor’s width and length were measured daily; after 24 days, the nude mice were sacrificed to excise the tumor. A Tumor images. B Weight of the tumors. *P < 0.05; **P < 0.01. C Growth curve of the tumors. **, P < 0.01. D The expression of Survivin in each group of tumor tissues (n = 3) was tested by Western Blot with indicated antibodies. **P < 0.01


In this study, the expression level of miR-198 was downregulated in RCC tissues compared with that in adjacent tissues in all 7 pairs of RCC samples (Fig. 2B). Moreover, the expression level of BIRC5 in RCC tissues was higher than that in adjacent tissues (Fig. 1). Owing to limitations in sample size, further studies with larger sample sizes to confirm that miR-198 is a potential marker of RCC are warranted.

miR-198 overexpression could significantly reduce cell viability and promote cell apoptosis by targeting BIRC5 (Fig. 3); furthermore, it can decrease cancer cell migration and invasion, whereas BIRC5 coexpression could reverse this effect (Fig. 4). The in vivo tumor growth model revealed that miR-198 could reduce the renal tumor size, weight, and growth rate; the tumor growth rate in the miR-198 inhibitor group was similar to that in the mimic group (Fig. 5). Therefore, it is highly likely that the low expression level of miR-198 is responsible for RCC development and tumor growth. Mechanistically, we showed that miR-198 inhibited renal cell growth by posttranslationally suppressing survivin levels by binding to the 3′-UTR of BRIC5 and reducing protein translation without affecting mRNA transcription (Fig. 2). Collectively, we conclude that BIRC5/survivin is a downstream target of miR-198. Similar to this finding, the upregulation of BIRC5 expression in RCC tissues and the promotion of tumorigenesis were reported by Zhang et al. [21]. More interestingly, Huang et al. showed that miR-198 as well as its potential target genes, including BIRC5, were downregulated in HCC [22]. These reports are all consistent with our results.

A previous study reported that low miR-198 expression in other types of tumors and miR-198 overexpression could inhibit tumorigenesis. For instance, miR-198 inhibits lung cancer cells and human osteosarcoma by directly targeting FGFR1 and ROCK1, respectively [24]. miR-198 inhibits via the targeting of [25]. However, Liang et al. showed that miR-198 contributed to the oncogenesis of lung adenocarcinoma by inducing livin expression but did not test the expression of miR-198 [13]. Furthermore, miR-198 inhibits HCC cells by targeting the HGF/c-MET pathway [9]. Additionally, miR-198 represses tumor growth and metastasis in colorectal cancer by targeting fucosyl transferase 8 [26]. These studies indicate that miR-198 plays a crucial role in tumorigenesis in various cancer types by targeting different downstream genes.


In summary, we demonstrated that miR-198 expression is repressed in RCC tissues. The overexpression of miR-198 inhibits A498 cell viability and migration, promotes cell apoptosis, and blocks tumor growth in xenograft nude mouse models. BIRC5 is a novel target in miR-198-mediated invasion and migration of RCC. We suggest that miR-198 is a potential biomarker and novel therapeutic target for RCC.

Availability of data and materials

All data generated or analyzed during this study are included in this article.



Renal cell carcinoma


Baculoviral inhibitor of apoptosis repeat-containing 5




Hepatocellular carcinoma


Polymerase chain reaction


Tyrosine kinase inhibitors


Mammalian target of rapamycin


Vascular endothelial growth factor


  1. Petejova, N, Martinek A. Renal cell carcinoma: review of etiology, pathophysiology and risk factors. Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia. 2016;160:183–94.

    Article  Google Scholar 

  2. Guo ZQ, Zheng T, Chen B, Luo C, Ouyang S, Gong S, Li J, Mao LL, Lian F, Yang Y, Huang Y, Li L, Lu J, Zhang B, Zhou L, Ding H, Gao Z, Zhou L, Li G, Zhou R, Chen K, Liu J, Wen Y, Gong L, Ke Y, Yang SD, Qiu XB, Zhang N, Ren J, Zhong D, Yang CG, Liu J, Jiang H. Small-molecule targeting of E3 Ligase adaptor SPOP in kidney cancer. Cancer Cell. 2016;30:474–84.

    Article  CAS  Google Scholar 

  3. Bazzi WM, Sjoberg DD, Feuerstein MA, Maschino A, Verma S, Bernstein M, O’Brien MF, Jang T, Lowrance W, Motzer RJ, Russo P. Long-term survival rates after resection for locally advanced kidney cancer: Memorial Sloan Kettering Cancer Center 1989 to 2012 experience. J Urol. 2015;193:1911–6.

    Article  Google Scholar 

  4. Sanchez-Gastaldo A, Kempf E, Gonzalez Del Alba A, Duran I. Systemic treatment of renal cell cancer: a comprehensive review. Cancer Treat Rev. 2017;60:77–89.

    Article  CAS  Google Scholar 

  5. Patil S, Manola J, Elson P, Negrier S, Escudier B, Eisen T, Atkins M, Bukowski R, Motzer RJ. Improvement in overall survival of patients with advanced renal cell carcinoma: prognostic factor trend analysis from an international data set of clinical trials. J Urol. 2012;188:2095–100.

    Article  Google Scholar 

  6. Brugarolas J. Renal-cell carcinoma–molecular pathways and therapies. N Engl J Med. 2007;356:185–7.

    Article  CAS  Google Scholar 

  7. Szabo Z, Szegedi K, Gombos K, Mahua C, Flasko T, Harda K, Halmos G. Expression of miRNA-21 and miRNA-221 in clear cell renal cell carcinoma (ccRCC) and their possible role in the development of ccRCC. Urol Oncol. 2016;34(533):e521-533 e527.

    Google Scholar 

  8. Tang K, Xu H. Prognostic value of meta-signature miRNAs in renal cell carcinoma: an integrated miRNA expression profiling analysis. Sci Rep. 2015;5:10272.

    Article  CAS  Google Scholar 

  9. Tan S, Li R, Ding K, Lobie PE, Zhu T. miR-198 inhibits migration and invasion of hepatocellular carcinoma cells by targeting the HGF/c-MET pathway. FEBS Lett. 2011;585:2229–34.

    Article  CAS  Google Scholar 

  10. Wu S, Zhang G, Li P, Chen S, Zhang F, Li J, Jiang C, Chen X, Wang Y, Du Y, Sun Q, Zhao G. miR-198 targets SHMT1 to inhibit cell proliferation and enhance cell apoptosis in lung adenocarcinoma. Tumour Biol J Int Soc Oncodev Biol Med. 2016;37:5193–202.

    Article  CAS  Google Scholar 

  11. Hu Y, Tang Z, Jiang B, Chen J, Fu Z. miR-198 functions as a tumor suppressor in breast cancer by targeting CUB domain-containing protein 1. Oncol Lett. 2017;13:1753–60.

    Article  CAS  Google Scholar 

  12. Quan XQ, Xie ZL, Ding Y, Feng R, Zhu XY, Zhang QX. miR-198 regulated the tumorigenesis of gastric cancer by targeting Toll-like receptor 4 (TLR4). Eur Rev Med Pharmacol Sci. 2018;22:2287–96.

    PubMed  Google Scholar 

  13. Liang Y, Wang H, Sun Y, Chen S, Wang H, Huang R, Zhao X, Fu W, Yang C. miR-198-induced upregulation of Livin may be associated with the prognosis and contribute to the oncogenesis of lung adenocarcinoma. Oncol Rep. 2017;38:2096–104.

    Article  CAS  Google Scholar 

  14. Jaiswal PK, Goel A, Mittal RD. Survivin: a molecular biomarker in cancer. Indian J Med Res. 2015;141:389–97.

    Article  Google Scholar 

  15. Lin TY, Chan HH, Chen SH, Sarvagalla S, Chen PS, Coumar MS, Cheng SM, Chang YC, Lin CH, Leung E, Cheung CHA. BIRC5/Survivin is a novel ATG12-ATG5 conjugate interactor and an autophagy-induced DNA damage suppressor in human cancer and mouse embryonic fibroblast cells. Autophagy 2020;16:1296–313.

    Article  Google Scholar 

  16. Liu SH, Hong Y, Markowiak S, Sanchez R, Creeden J, Nemunaitis J, Kalinoski A, Willey J, Erhardt P, Lee J, van Dam M, Brunicardi FC. BIRC5 is a target for molecular imaging and detection of human pancreatic cancer. Cancer Lett. 2019;457:10–9.

    Article  CAS  Google Scholar 

  17. Ungvari I, Hadadi E, Virag V, Bikov A, Nagy A, Semsei AF, Galffy G, Tamasi L, Horvath I, Szalai C. Implication of BIRC5 in asthma pathogenesis. Int Immunol. 2012;24:293–301.

    Article  CAS  Google Scholar 

  18. Parker AS, Kosari F, Lohse CM, Houston Thompson R, Kwon ED, Murphy L, Riehle DL, Blute ML, Leibovich BC, Vasmatzis G, Cheville JC. High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma. Cancer. 2006;107:37–45.

    Article  CAS  Google Scholar 

  19. Wang Z, Yuan C, Huang Y, Liu Z, Yu X, Lv C, Su Z. Decreased expression of apoptosis-inducing factor in renal cell carcinoma is associated with poor prognosis and reduced postoperative survival. Oncol Lett. 2019;18:2805–12.

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Si W, Xie W, Deng W, Xiao Y, Karnik SS, Xu C, Chen Q, Wang QK. Angiotensin II increases angiogenesis by NF-kappaB-mediated transcriptional activation of angiogenic factor AGGF1. FASEB J. 2018;32:5051–62.

    Article  CAS  Google Scholar 

  21. Zhang H, Li W, Gu W, Yan Y, Yao X, Zheng J. MALAT1 accelerates the development and progression of renal cell carcinoma by decreasing the expression of miR-203 and promoting the expression of BIRC5. Cell Prolif. 2019;52:e12640.

    PubMed  PubMed Central  Google Scholar 

  22. Huang WT, Wang HL, Yang H, Ren FH, Luo YH, Huang CQ, Liang YY, Liang HW, Chen G, Dang YW. Lower expressed miR-198 and its potential targets in hepatocellular carcinoma: a clinicopathological and in silico study. Onco Targets Ther. 2016;9:5163–80.

    Article  CAS  Google Scholar 

  23. Birkbak NJ, McGranahan N. Cancer genome evolutionary trajectories in metastasis. Cancer Cell. 2020;37:8–19.

    Article  CAS  Google Scholar 

  24. Zhang S, Zhao Y, Wang L. MicroRNA-198 inhibited tumorous behaviors of human osteosarcoma through directly targeting ROCK1. Biochem Biophys Res Commun. 2016;472:557–65.

    Article  CAS  Google Scholar 

  25. Yang J, Zhao H, Xin Y, Fan L. MicroRNA-198 inhibits proliferation and induces apoptosis of lung cancer cells via targeting FGFR1. J Cell Biochem. 2014;115:987–95.

    Article  CAS  Google Scholar 

  26. Wang M, Wang J, Kong X, Chen H, Wang Y, Qin M, Lin Y, Chen H, Xu J, Hong J, Chen YX, Zou W, Fang JY. MiR-198 represses tumor growth and metastasis in colorectal cancer by targeting fucosyl transferase 8. Sci Rep. 2014;4:6145.

    Article  CAS  Google Scholar 

Download references


Not applicable


This study was supported by the China National Natural Science Foundation young scholar grant (81902860) (W. S.), Hubei Polytechnic University School Talent introduction project (19XJK06R and 18XJZ04R) (W. S. and C. Y.), Hubei Nature Science Foundation (2014CFC1094 and 2019CFB184) (S. Z. and S. L.) and Huangshi Science and Technology Plan Project (2014A069-1) (S. Z.).

Author information

Authors and Affiliations



CY and ZS performed the most experiment, collected and analyzed the data, and drafted the manuscript. SL performed the corrected data. DLZZ, YW, MQand LZ assisted some experiment. CL, CS, WG, JW, XC, and WH helped to collect patient’s specimen. XL analyzed the specimen and helped to revise the manuscript. WS designed the experiment and drafted the manuscript. XY designed the experiment and super-revised the manuscript.

Corresponding authors

Correspondence to Xu Lv, Wenxia Si or Xin Yu.

Ethics declarations

Ethics approvaland consent to participate

This study was approved by the Ethics Committee of Hubei Polytechnic University and Haikou Municipal Hospital. All patients provided written informed consent.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1

: Figure S1. miR-198 does not affect the cell cycle. (A,B) A498 and ACHNcells were transfected with scrambled mimic of miR-198 and wild-type miR-198. After 36 h, the cells were analyzed using flow cytometry to assess their cell cycle. NS = no significant. (C,D) ACHNcells were treated like (A). NS = no significant.

Additional file 2

. The original data of RT-PCR and Western Blot.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yuan, C., Su, Z., Liao, S. et al. miR-198 inhibits the progression of renal cell carcinoma by targeting BIRC5. Cancer Cell Int 21, 390 (2021).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: